Carcinoma, Non-Small-Cell Lung
Conditions
Brief summary
The primary objective of this open-label, single arm Phase II trial is to explore the efficacy of BIBW 2992 defined by the objective response rate (CR, PR) as determined by the RECIST criteria, in patients with advanced NSCLC Stage IIIB or IV whose tumours harbour activating mutations within exon 18 to exon 21 of the EGFR receptor, in patients with mutations in the HER2/neu receptor and in patients with EGFR FISH positive tumours with no EGFR mutations.
Interventions
DRUGBIBW2992
tablet BIBW high dose
DRUGBIBW2992 + paclitaxel
tablet BIBW 2992 in combination with i.v. paclitaxel 3 weekly
Sponsors
Boehringer Ingelheim
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. patients with pathologically confirmed diagnosis of NSCLC stage IIIB/IV adeno- or bronchoalveolar carcinoma (BAC) 2. non smokers patients or patients having smoked less than 15 pack years and who stopped smoking for at least one year before diagnosis (except for patients with her2-neu mutation) 3. presence of activating mutation(s) in exon 18 to exon 21 of the EGFR or HER2-neu-receptor confirmed by direct DNA sequencing of NSCLC tumor tissue or increased copy number of the EGFR gene as determined by FISH analysis 4. prior treatment up to 3 lines of chemotherapy except for HER2-neu patients (no restrictions) no prior EGFR TKI therapy for EGFR mutation negative and FISCH positive patients 5. patients with at least one tumor lesion that can accurately be measured by CTscan or MRI in at least one dimension with long diameter to be recorded as \> or equal to 20 mm using conventional techniques or \> or equal to 10 mm with spiral CT scan 6. male or female patient aged above or equal to 18 years 7. life expectancy of at least 3 months 8. written informed consents that is consistent with ICH-GCP guidelines 9. ECOG performance score 0, 1 or 2
Exclusion criteria
1. more than 3 prior cytotoxic chemotherapy treatment regimen for relapsed or metastatic NSCLC, except for patients with HER2-neu mutations who may have received any prior therapy 2. Any chemo-, hormone- or immunotherapy within the past 4 weeks or within less than 4 half-lives of the previous drug prior to treatment with the trial drug and/or persistence of toxicities of prior anticancer therapies which are deemed to be clinically relevant 3. brain metastases which are symptomatic; patients with treated asymptomatic brain metastases are eligible with stable brain disease for at least 4 weeks without requirement for steroids or anti-epileptic therapy 4. significant or recent acute gastrointestinal disorders with diarrhea as a major symptom e.g. Crohn's disease, malabsorption or CTCAE Grade \> 2 diarrhea of any etiology at baseline 5. patients who have any other life-threatening illness or organ system dysfunction, which in the opinion of the investigator, would either compromise patient safety or interfere with the evaluation of the safety of the test drug 6. other malignancies diagnosed within the past 5 years (other than non melanomatous skin cancer and in situ cervical cancer) 7. radiotherapy within the past 2 weeks prior to treatment with the trial drug 8. patients with any serious active infection (i.e., requiring an IV antibiotic, antifungal, or antiviral agents) 9. patients with known HIV, active hepatitis B or active hepatitis C 10. known or suspected active drug or alcohol abuse 11. women of childbearing potential or men who are able to father a child unwilling to use a medically acceptable method of contraception during the trial 12. pregnancy or breast feeding 13. patient unable to comply with the protocol 14. history of clinically significant or uncontrolled cardiac disease, including congestive heart failure, angina, myocardial infarction, arrhythmia, including New York Heart Association (NYHA) functional classification of 3 15. Cardiac left ventricular function with resting ejection fraction of less than 50% measured by multigated blood pool imaging of the heart (MUGA scan) or Echocardiogram. 16. Absolute neutrophil count (ANC) less than 1500/mm³. 17. Platelet count less than 100 000 / mm³. 18. Bilirubin greater than 1.5 mg / dl (\>26 µmol / L, SI unit equivalent). 19. Aspartate amino transferase (AST) or alanine amino transferase (ALT) greater than three times the upper limit of normal (if related to liver metastases greater than five times the upper limit of normal). 20. Serum creatinine greater than 1.5 times of the upper normal limit
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants With Best Objective Response | Tumour assessments were performed at baseline (tumour assessment obtained within 4 weeks prior to beginning of treatment), week 8, and every 8 weeks thereafter. | Percentage of participants with best objective response: confirmed complete response (CR) or confirmed partial response (PR) according to RECIST version 1.0. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants With Disease Control (DC) | Tumour assessments were performed at baseline (tumour assessment obtained within 4 weeks prior to beginning of treatment), week 8, and every 8 weeks thereafter. | Percentage of participants with OR or stable disease (SD) as determined by RECIST version 1.0. |
| Progression Free Survival (PFS) Time | Tumour assessments were performed at baseline (tumour assessment obtained within 4 weeks prior to beginning of treatment), week 8, and every 8 weeks thereafter. | PFS time defined as time from the start of treatment to the earliest of progression (RECIST), clinical progression (investigator), start of new anti-cancer treatment or death. |
| Summary of Pre-dose Concentrations of Afatnib in Plasma | Day 15, 29 and 57 | Pre-dose Concentrations of Afatinib in Plasma at Steady State on Days 15, 29 and 57 (Cpre,ss,15, Cpre,ss,29 and Cpre,ss,57) |
Countries
Belgium, Spain
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Afatinib 50mg Afatinib 50mg film coated tablets were administered once daily as long as they were tolerated by patients, until disease progression (according to the response evaluation criteria in solid tumors) | 41 |
| Total | 41 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Dose reducing Event | 2 |
| Overall Study | Other | 1 |
| Overall Study | Other Averse Event | 7 |
| Overall Study | Progressive Disease | 21 |
| Overall Study | Protocol Violation | 1 |
| Overall Study | Switch to combination therapy | 8 |
| Overall Study | Withdrawal by Subject | 1 |
Baseline characteristics
| Characteristic | Afatinib 50mg |
|---|---|
| Age, Continuous | 60.7 years STANDARD_DEVIATION 13.4 |
| Sex: Female, Male Female | 26 Participants |
| Sex: Female, Male Male | 15 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 41 / 41 |
| serious Total, serious adverse events | 19 / 41 |
Outcome results
Primary
Percentage of Participants With Best Objective Response
Percentage of participants with best objective response: confirmed complete response (CR) or confirmed partial response (PR) according to RECIST version 1.0.
Time frame: Tumour assessments were performed at baseline (tumour assessment obtained within 4 weeks prior to beginning of treatment), week 8, and every 8 weeks thereafter.
Population: Treated set (TS). TS consisted of all patients who were dispensed study medication and have taken at least 1 dose of Afatinib.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Afatinib 50mg | Percentage of Participants With Best Objective Response | 2 Percentage of participants |
Secondary
Percentage of Participants With Disease Control (DC)
Percentage of participants with OR or stable disease (SD) as determined by RECIST version 1.0.
Time frame: Tumour assessments were performed at baseline (tumour assessment obtained within 4 weeks prior to beginning of treatment), week 8, and every 8 weeks thereafter.
Population: Treated set (TS). TS consisted of all patients who were dispensed study medication and have taken at least 1 dose of Afatinib.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Afatinib 50mg | Percentage of Participants With Disease Control (DC) | 59 Percentage of participants |
Secondary
Progression Free Survival (PFS) Time
PFS time defined as time from the start of treatment to the earliest of progression (RECIST), clinical progression (investigator), start of new anti-cancer treatment or death.
Time frame: Tumour assessments were performed at baseline (tumour assessment obtained within 4 weeks prior to beginning of treatment), week 8, and every 8 weeks thereafter.
Population: Treated set (TS). TS consisted of all patients who were dispensed study medication and have taken at least 1 dose of Afatinib.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Afatinib 50mg | Progression Free Survival (PFS) Time | 15.86 Weeks |
Secondary
Summary of Pre-dose Concentrations of Afatnib in Plasma
Pre-dose Concentrations of Afatinib in Plasma at Steady State on Days 15, 29 and 57 (Cpre,ss,15, Cpre,ss,29 and Cpre,ss,57)
Time frame: Day 15, 29 and 57
Population: Patients with no data available for the relevant parameter and dose were excluded from analysis.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Afatinib 50mg | Summary of Pre-dose Concentrations of Afatnib in Plasma | Cpre,ss,15 (N=13) | 35.0 ng/mL | Geometric Coefficient of Variation 74.9 |
| Afatinib 50mg | Summary of Pre-dose Concentrations of Afatnib in Plasma | Cpre,ss,29 (N=12) | 22.6 ng/mL | Geometric Coefficient of Variation 79.5 |
| Afatinib 50mg | Summary of Pre-dose Concentrations of Afatnib in Plasma | Cpre,ss,57 (N=5) | 27.9 ng/mL | Geometric Coefficient of Variation 96.1 |